Although QPS is complying with all government regulations for social distancing and allowing employees who can, to work from home, QPS Neuropharmacology is up and running. Please feel free to contact us any time to discuss your research needs.
QPS Neuropharmacology is the division of QPS that focuses on preclinical studies in CNS diseases, Orphan Diseases and Mental Disorders. The on-site availability of highly predictive disease models and unparalleled experience with studies performed for biopharmaceutical companies of all sizes makes QPS Neuropharmacology the first choice for most CNS drug development needs.
Validated transgenic and non-transgenic in vitro and in vivo models cover most targets of Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Niemann-Pick Disease, Autism Spectrum Disorder (ASD), Schizophrenia, Lewy Body Dementia (LBD) and other neurodegenerative diseases.
QPS is a global contract research organization (CRO) providing discovery, preclinical and clinical drug development services since 1995. Our mission is to accelerate pharmaceutical breakthroughs across the globe by delivering custom-built research services. An award-winning leader in the CRO industry, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction and turnkey laboratories and facilities.
QPS Neuropharmacology provides research services with numerous standardized cell culture systems including transgenic and non-transgenic cell lines, glial cells, primary chicken and rat peripheral and central nervous system neurons of different developmental stages and organotypic brain slices. New models are developed and validated on request.
As a leading CRO for CNS drug development, QPS Neuropharmacology is the premier provider for services with transgenic animals. The enterprise gained experience in generating, characterizing and maintaining transgenic disease models and using them for drug testing projects for more than 15 years.
QPS Neuropharmacology's expertise lies within the field of neurodegenerative diseases. We provide a state of the art research environment (AAALAC certified) for testing and evaluating new potential treatment approaches.
QPS Neuropharmacology's well characterized and validated n vivo models are useful tools to push your CNS drug discovery research forward. We are happy to support your research activities with sample material from our biobank composed of various specimen derived from our in-house in vivo models.
Different preformed recombinant human α-synuclein (α-syn) fibrils were evaluated for their toxicity and seeding properties on primary cortical neurons in vitro.
Our results show that monomeric human α-syn has no impact on cell viability, while preformed wild type and A53T human α-syn fibrils have toxic effects on primary cortical neurons. This toxic effect was exceeded by oligomeric isoforms (Fig.1A). Only A53T α-syn fibrils of the tested isotypes showed seeding properties in cortical neurons (Fig.1B).
Figure 1. In vitro assessment of α-syn preformed fibrils on mouse primary neurons. Toxicity (A) as well as seeding (B) properties of different preformed recombinant human α-syn species (Stressmarq) on mouse primary cortical neurons. (A) Neurons treated with α-syn species, and assessed for cell viability by MTT assay. (B) Neurons treated with α-syn species and immunocytochemically analyzed for murine α-syn. Mean+SD. One-way ANOVA with Bonferroni post hoc test (vs vehicle control: VC). ** p<0.01, *** p<0.001.
Figure 2. Representative images of endogenous murine α-syn accumulation after seeding with different preformed recombinant human α-syn species (Stressmarq). Neurons were treated with (A) monomeric and (B) A53T preformed fibrils and after incubation immunocytochemically stained for murine α-syn. Nuclear stain DAPI = blue; murine α-syn = red; scale bar 100 µM.
hA53T-Sud mice express A53T mutant human α-synuclein under the control of the murine Thy-1 promoter. This line M53 is bred on a C57BL/6J background (Chandra et al.2005).
Animals show the following phenotype:
The phenotype described above closely reflects PD pathology making the hA53T-Sud mouse a perfect model for your drug testing.